

3/29/2007; page 1

SUGGESTED FORMULATION

Ingredient Listing	Qty.	Unit	NDC #	Supplier	Lot Number	Expiry Date
Heparin Sodium 10,000 Units/mL Stock Solution †	5.00	mL				
Sodium Chloride, USP	0.056	g				
Benzyl Alcohol, NF	0.20	mL				
Sterile Water For Injection, USP	q.s. to 10.0	mL	8)		
† Heparin Sodium 10,000 Units/mL Stock Solution				N.		
Heparin Sodium (Powder) (1 MU), USP	1	Vial		×Y		
Sterile Water For Injection, USP	100.0	mL				



3/29/2007; page 2

Suggested F 001 515 Heparin Sodium 5000 Units/mL Injection (Solution, 10 mL) FIN Formula SPECIAL PREPARATORY CONSIDERATIONS Ingredient-Specific Information *Light sensitive* (protect from light whenever possible): Benzyl Alcohol *Hygroscopic* (protect from moisture whenever possible): Heparin Sodium Suggested Preparatory Guidelines Non-Sterile Preparation Sterile Preparation To account for processing error, sterility and endotoxin testing considerations during Processing Error / preparation, it is suggested to measure an additional 25 to 30% of the required Testing Considerations: quantities of ingredients. Special Instruction: This formula must be prepared within the appropriate facilities under adequate environmental conditions, following the necessary guidelines and procedures as stated within USP 797. Only trained and qualified personnel must prepare this formula. All heat stable, reusable materials and equipment must be sterilized and depyrogenated by dry heat sterilization at 250°C for 2 hours prior to use. Every batch of final product compounded using this procedure must be sterility and endotoxin tested before being dispensed. Protective apparel, such as a sterile gown, sterile gloves, shoe covers, head cap, evewear and face-masks should always be worn. In addition, proper personnel cleansing must be done before entering the buffer or clean area. Filter integrity must be validated by performing a filter stress test. If the test demonstrates that the filter might be defective, the solution must be discarded and remade. This procedure requires the use of very small quantities of ingredients. All calculations and preparation techniques must be verified before dispensing the final product.



3/29/2007; page 3

Suggested Formula	Heparin Sodium 5000 Units/mL Injection (Solution, 10 mL)	FIN	F 001 515	
----------------------	--	-----	-----------	--

SUGGESTED PREPARATION (for 10 mL)

Weigh and / or measure the following ingredients when appropriate:

Ingredient Listing	Qty.	Unit	Multiplication factor ^(*) :	Processing Error	Qty. to measure
Heparin Sodium 10,000 Units/mL Stock Solution § †	5.00	mL			
Sodium Chloride, USP §	0.056	g			
Benzyl Alcohol, NF §	0.20	mL	8		
Sterile Water For Injection, USP §	q.s. to 10.0	mL			
		Ċ			
† Heparin Sodium 10,000 Units/mL Stock Solution					
Heparin Sodium (Powder) (1 MU), USP §		Vial			
Sterile Water For Injection, USP §	100.0	mL			

* Takes into account increased batch size conversions and density conversions, if required.

§ Weigh / measure just prior to use.

Preparatory Instruction

IMPORTANT: All preparatory procedures must be performed using proper Aseptic Technique

1. Equipment sterilization:

Following the manufacturer's specifications, sterilize and depyrogenate all heat stable, reusable materials and equipment, then return to ambient temperature.



3/29/2007; page 4

	Heparin Sodium 5000 Units/mL Injection (Solution, 10 mL)	FIN	F 001 515
2.	† Heparin Sodium 10,000 Units/mL Solution preparation:		
	A. Add the Sterile water for injection (100.0 mL) into the following ingredient:		
	- Heparin Sodium (Powder) (1 MU) (1 vial)		
	Specification: Continuously mix until all solid particles have completely dissolved.		
	End result: Homogeneous liquid-like solution.		
3.	Liquid preparation:		
	A. Combine and mix the following ingredients together until homogeneously dispersed:		
	- Heparin Sodium 10,000 Units/mL Stock Solution (5.00 mL plus processing error adjustment	s)	
	- Benzyl Alcohol		
	End result: Homogeneous liquid-like solution.		
4.	Powder to medium integration:		
	A. Incrementally add the Sodium Chloride into the following ingredient:		
	- Homogeneous liquid-like solution (Step 3A)		
	Specifications: Continuously mix until all solid particles have completely dissolved.		
	End result: Homogeneous liquid-like solution.		
5.	Filling to volume and transfer into dispensing container:		
	A. Add Sterile Water For Injection to the mixture (Step 4A) to fill to the required batch size (10.0 processing error adjustments).	mL plı	ts
	Specifications: Continuously mix.		
	End result: Homogeneous liquid-like solution.		
	B. Transfer the final product into the recommended dispensing container (see Packaging requirem	ents).	
	Note: After sterilization, a sample is to be used as the Test sample for sterility testing.		



3/29/2007; page 5

	ggested Formula	Heparin Sodium 5000 Units/mL Injection (Solution, 10 mL)	FIN	F 001 515
6.		zation: ving the manufacturer's specifications, autoclave sterilize the mixture, then return to ambient re.	temper	ature and
	H H Pi	pecifications: eating temperature: 121°C eating time: 20 minutes ressure: 15 psi		
7.	Steril	<u>APORTANT</u> : The temperature of the heated chamber must reach 121°C before the exposure aty testing: ate the Test sample for sterility and endotoxins, in accordance to current USP 797 regulatory g		
		B. BORK		



3/29/2007; page 6

SUGGESTED PRESENTATION

Estima Beyond-Use D		14 days, refrigerated. BUD based on a successful sterility and endotoxin test result.	Packa Requirem		Sterile, light-resistant, heat stable injection vials.		
	1	Use as directed. Do not exceed dose.	l prescribed	6	Discard in the presence of particulate matter.		
	2	Keep out of reach of children.		7	Equilibrate to room temperature before use.		
Auxiliary	3	Keep refrigerated. Do not freeze.			Protect from light.		
Labels	4	Do not use if discolored.			Consult your health care practitioner if any other prescription or over-the-counter medications are currently being used or are prescribed for future use.		
	5	Discard container after use.)			
Pharmacist	Add any auxiliary labels specific to the API to the dispensing container as deemed necessary.						
Instructions	Important: To be administered only by the prescribing physician.						
Patient Instructions	Contact your pharmacist in the event of adverse reactions						



R

MEDISCA[®] NETWORK INC. TECHNICAL SUPPORT SERVICES FORMULATION CHEMISTRY DEPARTMENT TOLL-FREE: 866-333-7811 TELEPHONE: 514-905-5096 FAX: 514-905-5097 <u>technicalservices@medisca.net</u>

3/29/2007; page 7

E								
	Suggested Formula	FIN	F 001 515					
EF	ERENCES							
1	Tiepai	in Sodium. In: Sweetman SC, ed. <i>Martindale: The Complete Drug Reference, 34th Edition</i> . Lo aceutical Press; 2005: 928.	ondon,	England: The				
2	2. Heparin (Monograph). In: O'Neil MJ. <i>The Merck Index 13th Edition</i> . Whitehouse Station, NJ: Merck & Co, Inc.; 2001: 830.							
3	3. Heparin Sodium (Monograph). US Pharmacopeial Convention, Inc. <i>United States Pharmacopeia XXV / National Formulary 20</i> . Rockville, MD: US Pharmacopeial Convention, Inc; 2001: 836.							
4	4. Heparin Sodium. US Pharmacopeial Convention, Inc. <i>USP DI – Drug Information for the Health Care Professional, 26th Edition</i> . Taunton, MA: US Pharmacopeial Convention, Inc; 2006: 1626.							
5	5. USP <797> Pharmaceutical Compounding – Sterile Preparations. US Pharmacopeial Convention, Inc. United States Pharmacopeia XXVIII / National Formulary 23. Rockville, MD. 2004: 2461.							
		A B B ORK						